Lyuksfen drops Ch. 5ml 0.2%

Description

Composition
Active substance:
Brimonidine tartrate – 2.0 mg
Excipients:
benzalkonium chloride (in terms of 100% substance) – 0,052 mg, polyvinyl alcohol – 14.0 mg Sodium chloride – 6.90 mg, sodium citrate dihydrate, – 4.70 mg of citric acid monohydrate – 0.48 mg hydrochloric acid – to pH 6.45, sodium hydroxide – to pH 6.45, water – up to 1 ml
Description:
The clear solution is greenish-yellow in color
Product form:
0.2% eye drops.
5 mL vials of white low-density polyethylene with a transparent drip-packed, low density polyethylene and white screw cap of high density polyethylene with a first control opening. On the bottle label paste.
1 vial together with instructions for use placed in a cardboard box
Contraindications
Increased sensitivity to the drug.
Simultaneous treatment monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants.
Children under 2 years old.
Lactation.
Caution: when using the drug in patients with severe, unstable and uncontrollable form of cardiovascular disease, a cerebral or coronary insufficiency, depression,
orthostatic hypotension, Raynaud’s disease, thromboangiitis obliterans; at infringement of the liver or kidney; children age 2 to 18 years.
Dosage
0.2%
Indications
Open-angle glaucoma, ocular hypertension (in monotherapy or in combination with other drugs,
lowering intraocular pressure).
Interaction with other drugs
Brimonidine a concentration of 2 mg / ml may enhance the action of substances affecting the central nervous system (alcohol, barbiturates, opioids, sedatives and anesthetics).
Caution should be exercised in the case of taking the drugs capable of acting on the absorption and metabolisation into the blood adrenaline, noradrenaline and other so called biogenic amines (chlorpromazine, methylphenidate, reserpine).
In some patients, after administration of brimonidine solution in a concentration of 2 mg / ml there was a slight decrease in blood pressure. Caution should be exercised while the use of antihypertensive drugs and / or group of cardiac glycosides drugs (digitalis).
With simultaneous systemic administration of adrenergic agonists or antagonists (e.g., isoprenaline (regardless of their method of administration) may arise interaction with alpha-adrenergic agonists or exposure to their effects.
Overdose
Overdose observed rarely.
When accidentally taking the drug orally, the following symptoms: central nervous system depression, drowsiness, depression, and loss of consciousness, decreased blood pressure, bradycardia, decreased body temperature, skin cyanosis, apnea.
If you accidentally taking the drug inside: supportive symptomatic therapy, monitoring of airway patency.
pharmachologic effect
Pharmacological group:
Antiglaucoma agents – alpha 2-agonists selective
Pharmacodynamics:
Brimonidine – selective agonist of the alpha2-adrenergic receptors.
When instillation of 0.2% solution of brimonidine intraocular pressure reduction is 10-12 mm. Hg. Art.,
maximum action is noted after 2 hours, duration – 12 hours.
Brimonidine has a dual mechanism of action, it can lower the intraocular pressure by decreasing intraocular liquid synthesis and enhance uveoscleral outflow
Pharmacokinetics:
After applying an eye drop of 0.2% solution of brimonidine twice a day for 10 days, its plasma concentration remains low (average 0.06 ng / ml).
When an eye drop instillation maximum plasma concentration of the drug is achieved through 0.5-2.5
h half-life (T1 / 2) is about 2 hours.
Contact with the blood supply in the local application of 29%.
Systemic absorption of brimonidine slowed.
Drug metabolized primarily in the liver. Output brimonidine and its metabolites by the kidneys
Pregnancy and breast-feeding
safety studies and efficacy of brimonidine in pregnant and breast-feeding is not carried out. In animal studies, brimonidine topical application does not lead to violation of fetal development. There is no exact data on the penetration of breast milk brimonidine when applied topically. However, the risk can not be excluded completely. The use of brimonidine in pregnancy is allowed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus or child. In the appointment during lactation should stop breastfeeding during treatment.
Conditions of supply of pharmacies
On prescription
side effects
The incidence of adverse events classified as follows: very often (> 1/10), often (by> 1/100 to
special instructions
Before using the product, remove contact lenses. The time interval between the use of the drug and reinstalling the contact lenses must be at least 15 minutes.
Impact on the management of vehicles and the performance of potentially hazardous activities
The drug can induce a state of fatigue or sleepiness, decreased visual acuity, so the period of treatment should refrain from driving vehicles and moving machinery maintenance.
Storage conditions
Store at a temperature not higher than 25 ° C
Keep out of the reach of children
Dosing and Administration
Locally.
Buried 1 drop preparation 2 times a day.
Duration of treatment is determined by the doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist